Back to results
US 6,958,337 B2Granted
Crystalline antifungal polymorph
AssigneeSchering Corporation
InventorsDavid R. Andrews, William Leong, Anantha Sudhakar
Life of this patent
Estimating the term…
Abstract
The crystalline polymorph Form I of (−)-4-[4-[4-[4-[[(2R-cis)-5-(2,4-difluorophenyl)tetrahydro-5-(1H-1,2,4-triazol-1-ylmethyl)furan-3-yl]methoxy]phenyl]-1-piperazinyl]phenyl-2,4-dihydro-2-[(S)-1-ethyl-2(S)-hydroxylpropyl]-3H-1,2,4-triazol-3-one represented by the formula I pharmaceutical compositions containing such a polymorph and methods of using such a polymorph to treat fungal infections in mammals are disclosed.
Claims7
A crystalline polymorph Form I of the compound represented by the formula I
- and characterized by at least one of the following properties:
- a melting point range of about 164 to about 165° C. wherein the melting point range is determined using USP Class Ia procedure;
- a specific rotation equal to [a]25D=−29.4° wherein the specific rotation is determined using a concentration of 10 mg/ml in methanol;
- an X-ray powder diffraction pattern substantially similar to that presented in FIG. 1;
- a differential scanning calorimetry thermogram substantially similar to that presented in FIG. 7;
- or
- the proton NMR spectrum substantially similar to that presented in FIG. 10.
4 more elements
A crystalline polymorph Form III of the compound represented by the formula I
- and characterized by an X-ray powder diffraction pattern displaying d spacing peaks at 28.69, 14.45, 10.59, 7.27, 6.59, 4.14, 3.58, and 3.53 +/−0.04.
Dependencies are inferred from the claim text.